Olympus announces acquisition of FH ORTHO, an international ...

https://www.yahoo.com/.../olympus-announces-acquisition-fh-ortho- 060000860.html
site-preview

Nov 1, 2020 ... To expand Minimally Invasive Surgery field by reinforcing its orthopedics business Tokyo, Japan & Hamburg, Germany--(Newsfile Corp. Yahoo is part of Verizon Media. Your personal data that may be used Information about your device and internet connection, including your IP address Browsing and search activity while using Verizon Media websites and apps



Olympus announces acquisition of FH ORTHO, an international ...

https://www.olympus-global.com/news/2020/nr01926.html
site-preview

Nov 2, 2020 ... Olympus announces acquisition of FH ORTHO, an international orthopedics company in France To expand Minimally Invasive Surgery field by ... Olympus announces acquisition of FH ORTHO, an international orthopedics company in France To expand Minimally Invasive Surgery field by reinforcing its orthopedics business Tokyo/Hamburg, November 2, 2020 – Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has acquired FH ORTHO SAS, an international orthopedic company headquartered in Heimsbrunn, France, following the close of a definitive agreement the two companies signed in the summer of 2020. The acquisition underscores Olympus’ commitment to expanding in the growing field of orthopedic minimally invasive surgery (MIS) both organically and through mergers and acquisitions, with the overarching goal of developing innovative solutions that improve clinical outcomes, reduce overall costs and enhance quality of life for patients. News Release Details (PDF: 572.5KB) Press releases are company announcements that are directed at the news media. Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate. Olympus announces acquisition of FH ORTHO, an international orthopedics company in France



Olympus announces acquisition of French orthopedics company

https://www.biospectrumasia.com/.../olympus-announces-acquisition-of- french-orthopedics-company.html
site-preview

Nov 3, 2020 ... Olympus Corporation, based in Japan, has announced that it has acquired FH ORTHO SAS, an international orthopedic company ... Welcome Guest Digital Edition Subscribe Newsletter Media Kit Login/Sign Up MedTech Medical Devices Olympus announces acquisition of French orthopedics company Olympus announces acquisition of French orthopedics company To expand the minimally invasive surgery field by reinforcing its orthopedics business Olympus Corporation, based in Japan, has announced that it has acquired FH ORTHO SAS, an international orthopedic company headquartered in Heimsbrunn, France, following the close of a definitive agreement the two companies signed in the summer of 2020. The acquisition underscores Olympus' commitment to expanding in the growing field of orthopedic minimally invasive surgery (MIS) both organically and through mergers and acquisitions, with the overarching goal of developing innovative solutions that improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. By acquiring FH ORTHO, Olympus builds on its portfolio of innovative and patient-focused solutions that are used in MIS procedures in ligament repair, foot & ankle, and trauma surgery. Olympus is already active in orthopedics in Japan, where its joint venture Olympus Terumo Biomaterials Corp. distributes products such as bone substitutes and high tibial osteotomy (HTO) plates and screws. Beyond this, Olympus has also developed the first ultrasound device indicated for arthroscopic surgery, supporting more accurate and safer cutting of bones. The acquisition of FH ORTHO will strengthen Olympus group's sales channels by enabling it to expand the distribution of both Olympus' orthopedic products via FH ORTHO's existing distribution channels, as well as to sell certain FH ORTHO key products in Japan.



Novartis successfully completes acquisition of The Medicines ...

https://www.novartis.com/.../novartis-successfully-completes-acquisition- medicines-company-adding-potentially-first-class-investigational-cholestero...
site-preview

Jan 6, 2020 ... As a result of the merger, the Company became an indirect ... potentially, patient outcomes for the millions of people living with ASCVD or FH.”. Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1 The Medicines Company submitted the New Drug Application (NDA) for inclisiran to the FDA in December 2019 Comprehensive Phase III inclisiran program showed potent and durable reduction of >50% in LDL-C on top of standard of care, with excellent safety profile2,3,4 Adds potentially soon-to-launch, first-in-class investigational product, leveraging significant synergies with existing global cardiovascular commercial capabilities Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company surviving the merger, without a vote of the Company’s stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. In the merger, each share of the Company’s common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Company’s treasury or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) has been converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding. As a result of the merger, the Company became an indirect wholly-owned subsidiary of Novartis and the Company’s shares have ceased to be traded on the NASDAQ Global Select Market.









Ads